Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China.
Department of Urology, Jingzhou First People's Hospital, Jingzhou, China,
Oncol Res Treat. 2020;43(6):264-275. doi: 10.1159/000505931. Epub 2020 May 13.
Golgi alpha-mannosidase II (GM II) is one of the crucial enzymes in the process of N-glycan processing. The aim of our study was to examine the clinical significance of GM II in patients with clear cell renal cell carcinoma (ccRCC).
Quantitative reverse transcription polymerase chain reaction analysis and immunohistochemical staining were used to analyze GM II expression in patients with ccRCC. The clinical data of 62 patients with ccRCC were collected to analyze the clinical significance of GM II. The clinical significance among GM II expression, clinicopathological staging, and histological grade of ccRCC was explored. Survival analyses were performed to identify the relevance between the expression of GM II and the overall survival of patients with ccRCC. A uni-/multivariate Cox regression model was used to detect risk factors affecting the prognosis of patients with ccRCC. Subsequently, the proliferation and migration of ccRCC cells were detected after transfecting with GM II-short hairpin RNA (shRNA).
The results of these comparisons suggested that GM II expression of ccRCC tissues was dramatically higher than that of para-carcinoma tissues (p < 0.05). GM II expression in the high-differentiation group was lower than that in the median- and low-differentiation groups (p < 0.05). GM II expression in stage I and II tissues was lower than that in stage III and IV tissues (p < 0.05). The expression levels of GM II in the group without lymph node metastasis were lower than those in the group with lymph node metastasis (p < 0.05). Survival analysis indicated that patients with ccRCC with high GM II expression generally had decreased overall survival. Uni-/multivariate Cox model analyses further suggested an association between GM II expression and prognosis of patients with breast cancer. High GM II expression is a potential and independent prognostic biomarker in ccRCC. The inhibition of GM II by transfecting with GM II-shRNA could reduce the proliferation and migration of ccRCC.
GM II expression in human ccRCC tissues was upregulated compared with that found in normal human renal tissue, and GM II may promote the progression and migration of ccRCC. Furthermore, the GM II gene may be used as a promising tumor marker for the diagnosis and prognosis of ccRCC.
高尔基糖蛋白α-甘露糖苷酶 II(GM II)是 N-糖基化加工过程中的关键酶之一。本研究旨在探讨 GM II 在透明细胞肾细胞癌(ccRCC)患者中的临床意义。
采用定量逆转录聚合酶链反应分析和免疫组织化学染色分析 ccRCC 患者 GM II 的表达。收集 62 例 ccRCC 患者的临床资料,分析 GM II 的临床意义。探讨 GM II 表达与 ccRCC 临床病理分期和组织学分级的临床意义。通过生存分析确定 GM II 表达与 ccRCC 患者总生存率的相关性。采用单因素/多因素 Cox 回归模型检测影响 ccRCC 患者预后的危险因素。随后,转染 GM II-shRNA 检测 ccRCC 细胞的增殖和迁移。
这些比较结果表明,ccRCC 组织中 GM II 的表达明显高于癌旁组织(p<0.05)。高分化组 GM II 的表达低于中低分化组(p<0.05)。Ⅰ期和Ⅱ期组织中 GM II 的表达低于Ⅲ期和Ⅳ期组织(p<0.05)。无淋巴结转移组 GM II 的表达低于有淋巴结转移组(p<0.05)。生存分析表明,ccRCC 患者 GM II 高表达者总生存率降低。单因素/多因素 Cox 模型分析进一步提示 GM II 表达与乳腺癌患者的预后相关。GM II 高表达是 ccRCC 的一个潜在独立预后标志物。GM II-shRNA 转染抑制 GM II 的表达可降低 ccRCC 的增殖和迁移。
与正常人类肾组织相比,人 ccRCC 组织中 GM II 的表达上调,GM II 可能促进 ccRCC 的进展和迁移。此外,GM II 基因可能作为 ccRCC 诊断和预后的有前途的肿瘤标志物。